Phase 2 Single Arm, Two Cohort Study Evaluating AMG 337 in Subjects with MET Amplif. GI/GEJ/E cancer
What is the purpose of this trial?
Determine antitumor activity of AMG 337 in subjects with MET amplified gastric, (G)
gastroesophageal junction (GEJ), or esophageal (E) adenocarcinoma (Cohort 1).
- 18 Years and older
- Amgen, Inc.
- Last Updated:
- Study HIC#: